公开(公告)号：US11819544B2

公开(公告)日：2023-11-21

申请号：US16954337

申请日：2018-12-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Amirreza Faridmoayer ,  Sabina Marietta Gerber ,  Stefan Jochen Kemmler

IPC: A61K39/085 ,  A61K47/64 ,  A61K39/00 ,  C07K14/31

CPC classification number: A61K39/085 ,  A61K47/646 ,  C07K14/31 ,  A61K2039/6068

Abstract: The present invention discloses modified Staphylococcus aureus ClfA proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified ClfA protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the modified ClfA protein.

公开(公告)号：US11286283B2

公开(公告)日：2022-03-29

申请号：US16954306

申请日：2018-12-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Martin Braun ,  Amirreza Faridmoayer ,  Sabina Marietta Gerber ,  Markus Mueller

IPC: C07K1/00 ,  C07K14/31 ,  A61K47/64 ,  A61K39/085 ,  C12N9/10 ,  A61K38/00

Abstract: The present invention discloses modified Staphylococcus aureus HIa proteins which show reduced tendency to aggregate, improving protein stability and yield. Said modified HIa proteins optionally also contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified HIa protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked to an amino acid residue of the modified HIa protein.